Polyphor AG a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance announced that the company will present at the UBS Global Healthcare Virtual Conference, taking place May 24 -26, 2021.
ALLSCHWIL, Switzerland, May 18, 2021 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance today announced that the company will present at the UBS Global Healthcare Virtual Conference, taking place May 24 -26, 2021. Gokhan Batur, CEO of Polyphor, will provide an overview of the company and its pipeline and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. A replay of the presentation will be available for 30 days following the conclusion of the event.
Presentation details:
Date: Wednesday May 26, 2021
Time: 09:00 a.m. EDT; 15.00 CET, 2.00 p.m. BST
Presentation: Link to presentation
Online Registration: Conference website
For further information please contact:
For Investors:
| Hernan Levett Chief Financial Officer Polyphor Ltd. +41 61 567 16 00 IR@polyphor.com | Mary-Ann Chang LifeSci Advisors Tel: +44 7483 284 853 mchang@lifesciadvisors.com |
For Media:
Bernhard Schmid
LifeSci Advisors
+41 44 447 12 21
bschmid@lifesciadvisors.com
About Polyphor
Polyphor is a research driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance leveraging the company’s leading macrocyclic peptide technology platform. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company’s lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com.
Disclaimer
This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor’s results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
